Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In addition, replacing the current CRO with new CRO and more sites probably part of fund raising.
If the results come in May, then May it is.
May means may happen Monday May 9, another May day or whenever before or on May 31, but probably not June 1 or later.
Seems like ctix would be looking more for a midstage partnership like JNJ did with Pharmacyclics drug Imbruvica. And several years more to investigate what other type cancers with combinations of drugs it maybe effective against before pinning a final sale value on it.
******e*k Figure it out...read the trials importance and upcoming results these next three months.
Thanks.
6 of the 9 clinical trials sites for Prurisol were in Florida.
5 of those 6 in Florida are real close to one another in
distance...the Miami area -- (Pembroke Pines being the furthest
from Miami at about 22 miles by car). Only Kissimmee is far away from
Miami (217 miles).
Interesting to know if this closeness would bring out communicative
results from Prurisol trial during lunch hour breaks or on the golf
courses. Just a thought, no definitive surety.
United States, Florida
Cellceutix Study Center
Coral Gables, Florida, United States, 33134
Cellceutix Study Center
Hialeah, Florida, United States, 33016
Cellceutix Study Center
Kissimmee, Florida, United States, 34741
Cellceutix Study Center
Miami, Florida, United States, 33126
Cellceutix Study Center
Miami, Florida, United States, 33144
Cellceutix Study Center
Pembroke Pines, Florida, United States, 33026
Do the people running the Prurisol clinical sites only know the results for their site after the last patient visit for the whole trial, or do results from other clinical sites become known within a few weeks of trial end (crosstalk between sites about results)?
No news again and stable upward climb in price today to start the week.
This is actually directed to anyone who may know more about data revelation.
Major new BOD member from Big Pharma Company...but wait maybe they want 3 more weeks to buy undervalued, cheap stock...so maybe the collaboration partner for the kevetrin retinoblastoma trial(WAG)...or maybe a grant filing for Kevetrin AML trial (a nutter WAG).
Yeah, but no news today...seems something behind the scenes we don't know about yet that could lay the groundwork for new trading range these next few months...IMHO.
Wow! No news publicly and a nice upturn. Is this a potential partner buying up shares or Leo/Menon buying? Hope we can maintain this move for awhile.
Thanks Karin...Hope to read when I get access.
Maybe a little more preciseness is here:
http://www.plainsite.org/dockets/2ninter8g/new-york-southern-district-court/zagami-v-cellceutix-corporation-et-al/
Check out #40 Filed: 3/1/2016 Entered: 3/2/2016
Maybe last day to file and day put to docket are not always the same day - staff entering data is behind on cases.
Anyone here understand law response filings...if it is filed by today, does this mean Ashcroft can start working on their response (as only they can see it - not the public) or do they have to wait for it to go to docket (before they can view it) and lose the weekend to work on this??
Let's find a partner and get B-ABSSSI thru to approval. Then, we may bring JNJ (or whoever the secret tester is) into the biofilms contract. And get BOM and/or Prurisol to Phase 3 with minimal dilution.
OOOHHH forgot about Kevetrin. If we can get grants for phase 2's trials great!! and an intermission look at results like the BOM trial.
Hoping BOM intermediate results are readied by mid to late April.
I'm hoping as well they find the name and location of the anonymous person who wrote the article so he is held accountable in court. Goes for seeking alpha as well.
Merry Christmas Karin and a Healthy Happy New Year.
Thanks for the Christmas graphs of the CTIX barcharts of advancing progress. Hopefully, in 2016-2018 they get wider and more advanced and become the hope for many needing top quality medications to stay alive or get healthier with greater success.
Agreed. Go after Mako, Seeking Alpha and Rosen. They acted way outside their bounds of professional behavior and what's to be lawfully expected. Very slanderous with obvious personal motives and many untruths. Don't want this to happen repeatedly to other small biotechs. Hopefully, this judge is proactive for keeping unqualified non-professional investment advisors and writers from publishing slanderous, false materials before they can be verified by 1) real investment sources within the industry, 2) verified by the company being attacked, and 3) the proper research time to verify by greedy lawyers. Hopefully, criminal charges are pending for Mako and its cobweb of connections, a hefty fine for Seeking Alpha, Seeking Alpha be enforced to put warnings about these type of slanderous and possibly criminal articles on their website and that lawyers will not be able to ambulance chase so quickly without fair time and due diligence, otherwise face sanctions for doing so. C'mon Judge make this a landmark case.
I'm compiling my questions this weekend, would love to be there, but Dec 15 as stated before this morning, is not common time meeting so close to the holidays, hope there are good things behind this choice of date. And hopefully, one of you will accept my questions and represent me in live face to face mode where maybe some great discussions will evolve. Thanks!
Yes, we shall see - he is ahead of us on knowing the news going on behind the scenes - K trial should be done soon if not already in terms of final cycle and patient.
If big news as in K P1 results, guessing Monday am/pm, so it can be digested by shareholders and give them time to generate any questions at Tues shareholder meeting JMHO FWIW
Outstanding work Slcimmuno - thanks for the BTD slides - cheers!
Thanks Youssef - I can't make it this year. I will email some questions to Leo as representation of not being there. Although I would rather be at meeting as discussions may lead to new questions.
Yes, your correct... mentioned in the below 2014 article about Dr Reddy formulating Prurisol and indications of Brilacidin.
http://www.outsourcing-pharma.com/Contract-Manufacturing/Cellceutix-hires-Dr.-Reddy-s-to-formulate-candidate-eye-drug
Karin...appears Prurisol is done recruiting.
You have insider information?? What kind of brainage do you have that the science is failing?
It doesn't take a strong management team to announce a reverse split.
You have no insider information on CTIX and who they may be talking
with that they have not reverse split yet.
I'm here for for Brilacidin and the science represented by current
trial results which are progressing very well for a company this size.
A LICENSE/PARTNERSHIP could come anytime IMHO
Cellceutix (CTIX) is closely advancing to a Phase 3 trial for ABSSSI. In phase 2B, a 1 day dose of CTIX's Brilacidin-ABSSSI showed equivalent efficacy to a 7 day dose of Daptomycin (better known as Cubicin) owned by Cubist Pharmaceuticals.
In December 2014, Cubist Pharmaceuticals was bought out by Merck for
8.4 billion. Daptomycin (Cubicin) acccounts for 80% of Cubist Pharmaceuticals sales.
Click on the link below to READ the content about this.
December 2014 Merck acquires Cubist Pharmaceuticals for 8.4 billion
A license deal is capable of happening even at what could be possibly two months before the Phase 3 trial starts.
Below is detailed a past example of a 5 WEEK - 2 MONTH gap between a LICENSING AGREEMENT and the start of a Phase 3 study for
Trius Pharmaceutical's antibiotic for ABSSSI (acute bacterial skin and skin structure infections).
FACTS:
July 27, 2011 Trius Pharmaceuticals license deal 94 million
Trius Pharmaceuticals signs a license deal with BIG PHARMA Bayer. Trius Pharmaceuticals retains the rights of their antibiotic ownership for USA, Canada, and Europe regions in this past deal.
Click on the link below to READ the content about this.
Trius Pharmaceuticals 94 million license deal
Trius Pharmaceuticals license deal July 27 2011 within 5 weeks - 2 month of phase 3 startup
September 2011 start of Trius Pharmaceuticals Phase 3
Yes, the FDA's clinicaltrials.gov site shows the START DATE of September 2011 for the Trius Pharmaceutical Phase 3 trial.
Click on the link below to READ the content about this.
FDA clinicaltrials.gov showing September 2011 start date for Trius Pharmaceutical's Phase 3
Trius Pharmaceuticals was bought out by Cubist Pharmaceuticals in July 2013.
Click on the link below to READ the content about this.
Trius Pharmaceuticals bought by Cubist Pharmaceuticals for $707 million
Cubist buyout of Trius Pharmaceuticals in July 2013.
Merck buys out Cubist Pharmaceuticals. Daptomycin antibiotic generates about 80% of its sales
Yes, this is a snippet from the March 24 2015 CTIX company news after finishing cohort 10 at 450 mg/m2
"This is great news that the tenth cohort has been completed, once again demonstrating the safety of Kevetrin. Our team is excited by the fact that no dose limiting toxicity (DLT) has been seen even at these higher levels, as DLT has historically been a significant hurdle for any biotech targeting p53. As such, we’re going to continue to push our novel drug as far as possible for maximum therapeutic effect and to collect the most robust data set possible,” commented Dr. James Alexander, Chief Operating Officer at Cellceutix. “We have seen some encouraging data in different types of cancer to date and the eleventh cohort gives us the opportunity to add to our knowledge base in preparation for future clinical studies."
A LICENSE/PARTNERSHIP could come anytime IMHO
Below is detailed a past example of a 5 WEEK - 2 MONTH gap between a LICENSING AGREEMENT and the start of a Phase 3 study for
Trius Pharmaceutical's antibiotic for ABSSSI (acute bacterial skin and skin structure infections).
FACTS:
July 27, 2011
Trius Pharmaceuticals signs a license deal with BIG PHARMA Bayer. Trius Pharmaceuticals retains the rights of their antibiotic ownership for USA, Canada, and Europe regions in this past deal.
Click on the link below to READ the content about this.
Trius Pharmaceuticals license deal July 27 2011 within 5 weeks - 2 month of phase 3 startup
September 2011
Yes, the FDA's clinicaltrials.gov site shows the START DATE of September 2011 for the Trius Pharmaceutical Phase 3 trial.
Click on the link below to READ the content about this.
FDA clinicaltrials.gov showing September 2011 start date for Trius Pharmaceutical's Phase 3
Trius Pharmaceuticals was later bought out by Cubist in July 2013.
Click on the link below to READ the content about this.
Cubist buyout of Trius Pharmaceuticals in July 2013
Cellceutix (CTIX) is closely advancing to a Phase 3 for ABSSSI. My point here is as referenced in the above example, a license deal is capable of happening even at what could be possibly two months
before a Phase 3 trial starts for any biotech company.
Is this the PUMA your talking about...
http://www.siliconinvestor.com/readmsg.aspx?msgid=25884443
One would think we can find a partnership for Brilacidin.
Look at this deal and not even in clinical trials yet.
http://www.bizjournals.com/boston/blog/bioflash/2015/08/aveo-the-cambridge-biotech-that-refuses-to-die.html?ana=yahoo
We will be in Phase 3 for B-ABSSSI - 1 day dose equivalent to Cubist 7 day daptomycin (the king).
I'm probably in as well. Have not sold anything during the timeframe in question including the punk event of Aug 6. Like others stated, maybe you should run the idea thru Leo Ehrlich as well. Thanks for doing this.
Correct paying for drug potential (what revenue strength a drug could could add to their current drug assets over a long period time and if its a platform that can be expanded to other indications all wrapped in the risk/reward possibility), not an exchange listing. I'm here for Brilacidin and excited that K is going to Phase 2 with the hope other tumors involved besides ovarian and maximized dosage and frequency now going to be put on display!!
What might he be hiding?? If any deals are being worked, we won't know about it before he does, then he won't hide it and make it public. I think having P, BOM and B-ABSSSI soon to follow is a wise move. If BOM and P finish b4 B-ABSSI, then possibly a deal for one of these two (if one/both work), and can ride out B-ABSSI further into Phase 3. IMHO
Its unfortunate that lawyers are (i won't say it cuz its something ---
ASCO presentation back in May, my bold below -- like this sentence going forward next year. Hopefully the customers waiting to test Kevetrin will be re-appearing after K Phase 1.
"The Cellceutix poster at ASCO brought great interest to Kevetrin with data suggesting that Kevetrin can reactivate p53 with very limited toxicity as a front-line treatment for cancer," stated Dr. Krishna Menon, Cellceutix Chief Scientific Officer. "Although the framework of the trial and ASCO guidelines prevented us from disclosing certain information, these experienced scientists took note of the gynecological cancer patients in the trial and extrapolated the data to pose many questions. Several companies and institutions wanted to discuss the possibility of Kevetrin in combination with their drugs or therapies to potentially increase efficacy and reduce or avoid side effects in a variety of cancers, including some rare, hard-to-treat and pediatric cancers. This is akin to the Kevetrin and sunitinib combination tested in a renal cancer line that generated very optimistic results. Kevetrin will continue to be developed in collaborations to become the compound of choice for the treatment of many cancers."
Univ Bologna Kevetrin for AML should start out Phase 2 with 100 patients. Please correct me if I'm wrong.
Hi Youssef, thanks for your representation at the meeting. And also your generous offers to take our questions. Like the photos - happy you had a great time and hope your family is finding ways to recover from your sister's passing. Thanks Again!
Maybe - just opinion - they expanded cohort 11 at the 750 mark if they are seeing another 1 or 2 tumor types that are starting to respond in a manner like the ovarian cancer tumors given ORPHAN DRUG designation. If so, probably make sense to check this or these tumor type(s) at 750 with expanded patients, before going to an increased dosage where a risk of a DLT might (who knows when) occur.
Most likely not, that's why these folks get away with it. Prey on the small companies using false journalism. SEC has bigger fish to fry.
Guess it won't happen at our level, would be nice to know if any Rosen people were trading ctix 1, 5, 10 days before yesterday, and what was the trading pattern like and what type of trades were done and the intensity between 9:30 and 4 pm yesterday. I thought somebody here said yesterday evening their brother worked for the SEC or was that on yahoo finance board last nite??